华润医药2023中期报告

Contents 02Corporate Profile03Corporate Information07Definitions12Management Discussion and Analysis53Other Information61Independent Review Report63Interim Consolidated Statement of Profit or Loss64Interim Consolidated Statement ofComprehensive Income65Interim Consolidated Statement ofFinancial Position67Interim Consolidated Statement ofChanges in Equity69Interim Condensed Consolidated Statementof Cash Flows73Notes to Interim Condensed ConsolidatedFinancial Information Corporate Profile 3320 China Resources Pharmaceutical Group Limited (stock code: 3320) is aleading integrated pharmaceutical company in China. Our businessencompasses manufacturing, distribution and retail of pharmaceuticaland healthcare products. Since the establishment in 2007, the Group hasdeveloped into one of the fifth largest pharmaceutical manufacturers andone of the third largest pharmaceutical distributors (by revenue) in China. In October 2016, the Company successfully completed its global offeringin Hong Kong. Our manufacturing business encompasses the researchand development, manufacturing and sale of pharmaceutical products.We manufacture 782 products comprising chemical drugs, Chinesemedicines and biological drugs as well as nutritional and healthcareproducts, covering a wide range of therapeutic areas includingcardiovascular, alimentary tract and metabolism, large-volume IV infusion,pediatrics, respiratory system, dermatological, etc. Moreover, we own arange of famous brands, such as “999”, “Dong-E-E-Jiao”, “DoubleCrane”, “Zizhu”, “Jiangzhong”,“Boya” and “KPC”, covering therapeuticareas including cold, gastroenterology, dermatology, pediatrics,orthopedics, plasma products, among others. In future, we will activelyexpand into health management and products for chronic diseasemanagement to meet the full-cycle and multi-dimensional healthcareneeds of Chinese households from prevention, healthcare, therapy torecovery. 782999 702,400 We regard R&D and product innovation as important drivers for our long-term growth and consistently increase the investment in R&D activities.We operate five State-certified engineering technology research centers,three State-certified enterprise technology centers and approximately 70provincially-accredited research centers, with a R&D team comprising over2,400 staff members. 2002814809DTP253145 Leveraging our comprehensive product supply and wide distributionnetworks, we directly distribute products to hospitals and other medicalinstitutions across the country. We operate a national distribution networkcomprising over 200 logistics centers strategically across 28 provinces,municipalities and autonomous regions in China, with over 140,000 clients,including around 10,000 second- and third-class hospitals and around70,000 primary medical institution clients. In addition, we comprise 809 retailpharmacies under national or regional premium brands — “CR Care()” and “Teck Soon Hong()”, etc, including 253 DTP specialtypharmacies (which cover 145 “dual channel()” pharmacies). Corporate Information BOARD OF DIRECTORS Chairman and non-executive DirectorMr. Han Yuewei Executive Director and Chief Executive OfficerMr. Bai Xiaosong Executive Director and Vice PresidentMr. Tao Ran Executive Director, Chief Financial Officer and Vice PresidentMdm. Weng Jingwen (resigned on 13 June 2023) Non-executive Directors Mr. Lin GuolongMdm. Guo Wei (appointed on 13 February 2023)Mr. Hou BoMdm. Jiao Ruifang Independent non-executive Directors Mdm. Shing Mo Han YvonneMr. Kwok Kin FunMr. Fu TingmeiMr. Zhang Kejian AUDIT COMMITTEE Mdm. Shing Mo Han Yvonne(Chairman)Mr. Lin GuolongMdm. Jiao RuifangMr. Kwok Kin FunMr. Fu TingmeiMr. Zhang Kejian Corporate Information NOMINATION COMMITTEE Mr. Han Yuewei(Chairman)Mdm. Shing Mo Han YvonneMr. Kwok Kin FunMr. Fu TingmeiMr. Zhang Kejian REMUNERATION AND APPRAISAL COMMITTEE Mr. Kwok Kin Fun(Chairman)Mr. Lin GuolongMdm. Shing Mo Han YvonneMr. Fu TingmeiMr. Zhang Kejian CORPORATE GOVERNANCE COMMITTEE Mr. Fu Tingmei(Chairman)Mr. Bai XiaosongMdm. Weng Jingwen (resigned on 13 June 2023)Mdm. Shing Mo Han YvonneMr. Kwok Kin FunMr. Zhang Kejian EXECUTIVE COMMITTEE Mr. Bai Xiaosong(Chairman)Mr. Tao RanMdm. Weng Jingwen (resigned on 13 June 2023) AUTHORIZED REPRESENTATIVES Mr. Bai XiaosongMdm. Weng Jingwen (resigned on 13 June 2023)Mr. So Yiu Fung (appointed on 13 June 2023) COMPANY SECRETARY Mr. Lo Chi Lik Peter (resigned on 13 June 2023)Mr. So Yiu Fung (appointed on 13 June 2023) LEGAL ADVISORS Clifford ChanceJia Yuan Law Offices AUDITOR KPMGPublic Interest Entity Auditor registered in accordance withthe Accounting and Financial Reporting Council Ordinance8th Floor, Prince’s Building10 Chater Road, Central, Hong Kong 108 REGISTERED OFFICE 41/F, China Resources Building26 Harbour RoadWanchaiHong Kong 2641 SHARE REGISTRAR Tricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong 1617 Corporate Information PRINCIPAL BANKERS Ag